SAN DIEGO–(BUSINESS WIRE)–Vividion announces publication on discovery and preclinical study of small molecules activating KEAP1 via a covalent molecular glue to degrade NRF2.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
